Brief: Calliditas: Supportive Interim Data From Phase 2 Head And Neck Cancer Trial With Lead NOX Inhibitor Candidate, Setanaxib
13/07/2023 07:06
July 13 (Reuters) - Calliditas Therapeutics AB
CALTX.ST :
* CALLIDITAS ANNOUNCES SUPPORTIVE INTERIM DATA FROM PHASE 2
HEAD
AND NECK CANCER TRIAL WITH LEAD NOX INHIBITOR CANDIDATE,
SETANAXIB
* ANALYSIS REFLECTS ENCOURAGING EARLY CLINICAL
PROGRESSION-FREE
SURVIVAL (PFS) RESULTS
Source text for Eikon: ID:nWkrgyNrF
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations